Emily Dattilo
Shares of Sage Therapeutics were trading lower after the biopharmaceutical company said it plans to slash a third of the workforce.
Sage stock dropped 5.5% to $6.87 in Thursday trading, while the S&P 500 gained 0.3%.
The company on Thursday announced a reshuffling of its business operations to support the ongoing launch of zurzuvae in postpartum depression and focus pipeline development efforts leading up to a clinical study for dalzanemdor in Huntington's disease planned for later this year.
The news follows disappointing results earlier this month from a study to evaluate the effects of a dalzanemdor in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.
The reorganization is expected to affect 165 employees (about 33% of the total workforce and about 55% of the company's research-and-development workforce), and includes changes to the leadership team. The move is planned to be substantially completed by the end of the fourth quarter.
It "is intended to enable Sage to strengthen its balance sheet, extend cash runway, and position the company for long-term growth potential," according to a company press release.
Write to Emily Dattilo at emily.dattilo@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
October 17, 2024 09:47 ET (13:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.